Baird Medical Investment Holdings Limited (BDMD)
NASDAQ: BDMD · Real-Time Price · USD
1.070
+0.080 (8.08%)
At close: Jun 26, 2026, 4:00 PM EDT
1.060
-0.010 (-0.93%)
After-hours: Jun 26, 2026, 5:34 PM EDT
Company Description
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People’s Republic of China.
The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation.
It sells its products through third-party distributors. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Baird Medical Investment Holdings Limited
| Country | China |
| Founded | 2012 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Haimei Wu |
Contact Details
Address: Baide Building, Building 11, Room 202, 2/F Guangzhou China | |
| Phone | 86 20 8218 5926 |
| Website | bairdmed.com |
Stock Details
| Ticker Symbol | BDMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001982444 |
| CUSIP Number | G0705H103 |
| ISIN Number | KYG0705H1039 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mark S. Saxton | Chief Executive Officer U.S. Subsidiary |
| Haimei Wu | Chairwoman of the Board of Directors and Chief Executive Officer |
| Quan Qiu | Chief Administrative Officer and Executive Director |
| Wei Hou | Executive Director |
| Jie Li | Acting Chief Financial Officer |
| Rongjian Lu | Chief Technology Officer and Deputy GM |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 22, 2026 | POS AM | Post-Effective amendments for registration statement |
| May 22, 2026 | F-3 | Filing |
| May 8, 2026 | SCHEDULE 13G | Filing |
| Apr 24, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 10, 2026 | 6-K | Report of foreign issuer |
| Jan 16, 2026 | 424B3 | Prospectus |
| Jan 15, 2026 | EFFECT | Notice of Effectiveness |
| Dec 5, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 5, 2025 | 6-K | Report of foreign issuer |